Literature DB >> 21884517

IL28B genotype does not correlate with HIV control in African Americans.

Mohammad M Sajadi1, Nahzinine Shakeri, Rohit Talwani, Charles D Howell, Ruth Pakyz, Robert R Redfield, Afshin Parsa.   

Abstract

BACKGROUND: HIV-1 natural viral suppressors (NVS) are individuals that control HIV replication without antiretrovirals (also know as HIV elite controllers). We have recently shown that these individuals have an elevated rate of hepatitis C virus (HCV) clearance. Given the association of IL28B genotype, specifically the rs12979860 single nucleotide polymorphism (SNP) based CC genotype, with HCV clearance, we studied its association with HIV control in 172 African American HIV subjects and 173 race-matched controls.
FINDINGS: The frequency of the CC genotype was 12.5% in the NVS, 14.7% in the LVL ("low viral load" cohort with 400-20,000 HIV-1 RNA copies/mL), 17.8% in the MHVL ("medium/high viral load" cohort with >20,000 HIV-1 RNA copies/mL), and 11.6% in an HIV-negative cohort. There was no statistical significance in the CC genotype distribution between these cohorts (p= 0.48 between the NVS and non-NVS HIV positive controls, p= 0.85 between NVS and HIV-negatives). We also did not observe any association between CC genotype distribution and HIV RNA viral load, as a continuous measure.
CONCLUSIONS: The IL28B CC genotype does not account for the noted HIV control in our specific NVS cohort. Further studies will be needed to determine if a common genetic factor can primarily account for any joint clearance of HCV and control of HIV.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21884517      PMCID: PMC3170134          DOI: 10.1111/j.1752-8062.2011.00307.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  10 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  HIV-1 natural viral suppressors: control of viral replication in the absence of therapy.

Authors:  Mohammad M Sajadi; Alonso Heredia; Nhut Le; Neil T Constantine; Robert R Redfield
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

3.  IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.

Authors:  Maureen P Martin; Ying Qi; James J Goedert; Shehnaz K Hussain; Gregory D Kirk; W Keith Hoots; Susan Buchbinder; Mary Carrington; Chloe L Thio
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

4.  Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors.

Authors:  Maria Salgado; Gregory D Kirk; Andrea Cox; Alleluiah Rutebemberwa; Yvonne Higgins; Jacquie Astemborski; David L Thomas; Chloe L Thio; Mark S Sulkowski; Joel N Blankson
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

5.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

Authors:  Hari S Conjeevaram; Michael W Fried; Lennox J Jeffers; Norah A Terrault; Thelma E Wiley-Lucas; Nezam Afdhal; Robert S Brown; Steven H Belle; Jay H Hoofnagle; David E Kleiner; Charles D Howell
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

6.  Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

Authors:  Norma I Rallón; Susanna Naggie; José M Benito; José Medrano; Clara Restrepo; David Goldstein; Kevin V Shianna; Eugenia Vispo; Alex Thompson; John McHutchison; Vincent Soriano
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

7.  Hepatitis C infection in HIV-1 natural viral suppressors.

Authors:  Mohammad M Sajadi; Nahzinine Shakeri; Rohit Talwani; Robert R Redfield
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

8.  Antiviral effect of interferon lambda against West Nile virus.

Authors:  Dongling Ma; Dong Jiang; Min Qing; Jessica M Weidner; Xiaowang Qu; Haitao Guo; Jinhong Chang; Baohua Gu; Pei-Yong Shi; Timothy M Block; Ju-Tao Guo
Journal:  Antiviral Res       Date:  2009-04-01       Impact factor: 5.970

9.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

  10 in total
  5 in total

1.  Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors.

Authors:  Mohammad M Sajadi; Roopa Pulijala; Robert R Redfield; Rohit Talwani
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

2.  Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis.

Authors:  Chrissa G Tsiara; Georgios K Nikolopoulos; Niki L Dimou; Katerina G Pantavou; Pantelis G Bagos; Benedicta Mensah; Michael Talias; Georgia G Braliou; Dimitra Paraskeva; Stefanos Bonovas; Angelos Hatzakis
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

Review 3.  HIV Diagnosis and Treatment through Advanced Technologies.

Authors:  Hafiza Fizzah Zulfiqar; Aneeqa Javed; Bakht Afroze; Qurban Ali; Khadija Akbar; Tariq Nadeem; Muhammad Adeel Rana; Zaheer Ahmad Nazar; Idrees Ahmad Nasir; Tayyab Husnain
Journal:  Front Public Health       Date:  2017-03-07

4.  Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers.

Authors:  Alice K Asher; Glenn-Milo Santos; Jennifer Evans; Emily K Dokubo; Tzong-Hae Lee; Jeffrey N Martin; Steven G Deeks; Leslie H Tobler; Michael Busch; Peter W Hunt; Kimberly Page
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

Review 5.  Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.

Authors:  S Chinnaswamy
Journal:  Genes Immun       Date:  2016-06-09       Impact factor: 2.676

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.